MERSANA THERAPEUTICS INC's ticker is MRSN and the CUSIP is 59045L106. A total of 129 filers reported holding MERSANA THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 4.48 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $181,828 | -23.3% | 143,172 | +98.7% | 0.00% | -100.0% |
| Q2 2023 | $237,021 | +70.1% | 72,043 | +112.5% | 0.00% | – |
| Q1 2023 | $139,337 | -82.4% | 33,902 | -74.9% | 0.00% | -100.0% |
| Q4 2022 | $792,278 | +29.7% | 135,201 | +49.5% | 0.00% | +100.0% |
| Q3 2022 | $611,000 | +465.7% | 90,413 | +286.4% | 0.00% | – |
| Q2 2022 | $108,000 | +111.8% | 23,400 | +84.1% | 0.00% | – |
| Q1 2022 | $51,000 | -56.0% | 12,712 | +3.1% | 0.00% | – |
| Q3 2021 | $116,000 | -30.5% | 12,330 | 0.0% | 0.00% | – |
| Q2 2021 | $167,000 | -77.8% | 12,330 | -73.4% | 0.00% | -100.0% |
| Q1 2021 | $751,000 | -30.4% | 46,415 | +14.5% | 0.00% | -50.0% |
| Q4 2020 | $1,079,000 | +24.2% | 40,550 | -13.1% | 0.00% | +100.0% |
| Q3 2020 | $869,000 | -29.6% | 46,649 | -11.6% | 0.00% | -50.0% |
| Q2 2020 | $1,235,000 | +946.6% | 52,759 | +161.1% | 0.00% | – |
| Q1 2020 | $118,000 | – | 20,207 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SILVERARC CAPITAL MANAGEMENT, LLC | 5,000,000 | $6,350,000 | 1.92% |
| VR Adviser, LLC | 11,328,000 | $14,386,560 | 1.51% |
| Bain Capital Life Sciences Investors, LLC | 8,663,673 | $11,002,865 | 1.23% |
| Affinity Asset Advisors, LLC | 2,850,000 | $3,619,500 | 1.02% |
| EcoR1 Capital, LLC | 19,364,688 | $24,593,154 | 0.83% |
| Altium Capital Management LP | 1,059,136 | $1,345,103 | 0.70% |
| 5AM Venture Management, LLC | 1,305,000 | $1,657,350 | 0.48% |
| Decheng Capital Management III (Cayman), LLC | 904,268 | $1,148,420 | 0.38% |
| COMMODORE CAPITAL LP | 2,244,378 | $2,850,360 | 0.33% |
| Philosophy Capital Management LLC | 2,342,634 | $2,975,145 | 0.32% |